A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy

被引：0
|
作者：
Khambati, Fatema [1 ]
Soliman, Hatem [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2395
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Development of GD2 and CD3 Targeted Bispecific T-Cell Engaging Antibodies for Neuroblastoma
    Patel, A.
    Thevanesan, C.
    Anderson, J.
    Pule, M.
    Straathof, K.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S136 - S137
  • [42] SPECIFIC ACTIVATION OF CD3+ CYTOTOXIC T-CELLS AGAINST THE TAG-72 TUMOR-ANTIGEN EXPRESSED ON GASTRIC-CANCER WITH BISPECIFIC ANTIBODIES
    HOMBACH, A
    TILLMANN, T
    ZIEGENHAGEN, DJ
    DIEHL, V
    KRUIS, W
    POHL, C
    GASTROENTEROLOGY, 1995, 108 (04) : A481 - A481
  • [43] A ROR1 SPECIFIC CD3 BISPECIFIC T-CELL ENGAGER ENGINEERED FOR SOLID TUMORS WITH AN EXPANDED THERAPEUTIC WINDOW
    Rabinovich, Brian
    Zhou, Xueyuan
    Takimoto, Jeffrey
    Song, Paul
    Alici, Evren
    Khanna, Nikhita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1110 - A1110
  • [44] A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
    Hipp, S.
    Tai, Y-T
    Blanset, D.
    Deegen, P.
    Wahl, J.
    Thomas, O.
    Rattel, B.
    Adam, P. J.
    Anderson, K. C.
    Friedrich, M.
    LEUKEMIA, 2017, 31 (08) : 1743 - 1751
  • [45] A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
    S Hipp
    Y-T Tai
    D Blanset
    P Deegen
    J Wahl
    O Thomas
    B Rattel
    P J Adam
    K C Anderson
    M Friedrich
    Leukemia, 2017, 31 : 1743 - 1751
  • [46] T-cell Immunotherapy and Cardiovascular Disease Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies
    Stein-Merlob, Ashley F.
    Ganatra, Sarju
    Yang, Eric H.
    HEART FAILURE CLINICS, 2022, 18 (03) : 443 - 454
  • [47] Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
    Fayon, Maxime
    Martinez-Cingolani, Carolina
    Abecassis, Audrey
    Roders, Nathalie
    Nelson, Elisabeth
    Choisy, Caroline
    Talbot, Alexis
    Bensussan, Armand
    Fermand, Jean-Paul
    Arnulf, Bertrand
    Bories, Jean-Christophe
    HAEMATOLOGICA, 2021, 106 (04) : 1193 - 1197
  • [48] Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials
    Shah, Zunairah
    Malik, Mustafa Nadeem
    Batool, Syeda Sabeeka
    Kotapati, Sravanthi
    Akhtar, Aisha
    Rehman, Owais Ur
    Ghani, Marium
    Sadiq, Maryam
    Akbar, Arshia
    Ashraf, Aqsa
    Farooqui, Arafat Ali Ali
    Yousaf, Muhammad Abdullah
    Ahmad, Muhaddis Ejaz
    Fazeel, Hafiz Muhammad
    Anwer, Faiz
    BLOOD, 2019, 134
  • [49] OPERATIONALIZING BISPECIFIC T-CELL ENGAGER (BITE) THERAPY ADMINISTRATION IN THE AMBULATORY ONCOLOGY SETTING
    Hall, Nicole
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [50] ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
    Harwood, Seandean Lykke
    Alvarez-Cienfuegos, Ana
    Nunez-Prado, Natalia
    Compte, Marta
    Hernandez-Perez, Sara
    Merino, Nekane
    Bonet, Jaume
    Navarro, Rocio
    Henegouwen, Paul M. P. van Bergen En
    Lykkemark, Simon
    Mikkelsen, Kasper
    Molgaard, Kasper
    Jabs, Frederic
    Sanz, Laura
    Blanco, Francisco J.
    Roda-Navarro, Pedro
    Alvarez-Vallina, Luis
    ONCOIMMUNOLOGY, 2018, 7 (01):
12345